Peptide ScheduleAdvanced Weight Loss Stack
Dual GIP/GLP-1 agonist for maximum appetite suppression combined with HGH fragment for targeted fat metabolism. Tirzepatide acts on both GIP and GLP-1 receptors for superior weight loss compared to single-agonist peptides, while AOD-9604 enhances lipolysis without affecting blood sugar or growth.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist, sold as Mounjaro (diabetes) and Zepbound (obesity). It targets two incretin hormones simultaneously, producing greater weight loss than semaglutide in head-to-head trials (up to 22.5% vs 15%). GIP activation enhances fat metabolism and may improve tolerability compared to GLP-1-only drugs.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2,500mcg | Weekly |
| Moderate | 5mg | Weekly |
| Aggressive | 10mg | Weekly |
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) specifically designed for fat metabolism. Unlike full HGH, it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or growth. It has GRAS (Generally Recognized As Safe) status in the US.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 500mcg | Daily |
Protocol Tips
- Tirzepatide requires slow titration — follow the GLP-1 titration protocol.
- AOD-9604 is best dosed fasted, ideally first thing in the morning.
- Nausea is common early on with Tirzepatide; it typically resolves within 1-2 weeks.
- Prioritize high-protein meals to preserve lean mass during weight loss.